Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
As Boehringer Ingelheim marches on with a €20 billion R&D game plan to get 15 more drugs approved in the next 7 years, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
